Key Takeaways for Sell and Stay Transitions
- A sell-and-stay transition lets owners cash out practice value while continuing to work under an employment agreement, which can support patient continuity and income during the handoff.
- Private-buyer deals usually involve a 30–90 day work-back with flat-fee compensation, while DSO affiliations often require multi-year employment with 25–35% of collections plus potential equity rollover.
- Employment contract terms, including compensation basis, non-compete scope, termination rights, and earnout protections, generally need to be negotiated before signing the letter of intent.
- Tax treatment can differ significantly: goodwill proceeds may qualify for capital-gains rates, while post-sale employment compensation is usually taxed as ordinary income.
- McLerran & Associates provides side-by-side valuations and negotiates on the seller’s behalf. Schedule a free, confidential discovery call to explore which path can fit your practice.
Post-Sale Work-Back Timelines by Buyer Type
The length of time a seller stays after closing usually depends on buyer type, patient loyalty to the doctor, and the owner’s retirement timeline. These factors can shape both the work-back period and the structure of compensation.
In a doctor-to-doctor sale, most transitions involve a 30–90 day work-back. During this period, the seller introduces patients to the incoming dentist, supports treatment-coordinator relationships, and manages referral handoffs. Many walk-away sales use a 4–8 week work-back, after which the seller exits completely. A longer period, sometimes up to 6 months, can be negotiated when the practice has an older, highly loyal patient base. Very extended arrangements can also create confusion about who is in charge, so balance matters.
In a DSO affiliation, a minimum 5-year post-close employment commitment is common, with some deals extending further based on earnout structure and equity vesting schedules. This structure usually functions as the mechanism through which a meaningful portion of total proceeds is earned over time. A portion of total DSO proceeds is commonly tied to production targets during a 3–5 year earnout period, so the seller’s continued clinical engagement can directly affect the final payout.
Patient retention data supports a structured transition. Average patient attrition following a well-handled sale can be under 10%, with outcomes strongly influenced by how the seller’s post-closing role is defined. Long-tenured hygienists and front-desk coordinators often serve as the continuity anchor for patients during ownership transitions. If key staff leave within 60 days of closing, retention can drop sharply. Early communication, retention incentives, and reassurance about job security are standard mitigation tactics recommended before going to market.
Key Employment Contract Terms After a Practice Sale
The employment agreement signed at close sets the seller’s income, autonomy, and legal exposure for years. Economic certainty terms, including post-closing employment length, compensation, and covenant scope, generally cannot be fixed later and therefore call for the strongest negotiation before signing the letter of intent (LOI). The LOI is the preliminary agreement that outlines deal terms before the final purchase contract is drafted.
The checklist below highlights terms that most often require active negotiation and careful review.
- Compensation basis. Production-based compensation formulas are generally more seller-favorable than collections-based formulas because collections can be affected by billing delays and write-offs outside the doctor’s control. Many sellers push for production as the base metric when possible.
- Schedule and hours. Define minimum and maximum clinical days per week in writing. Vague language about “full-time” can be interpreted broadly by a buyer who wants to increase production, so clarity can prevent future conflict.
- Non-compete scope. Non-compete clauses commonly run 2–5 years with a 5–10 mile geographic radius. Overly broad covenants that cover an entire state or region can be red flags and often merit negotiation down to the practice’s actual patient draw area. Placing the non-compete in the purchase agreement, not only in the employment agreement, can help ensure it survives termination.
- Termination rights. Termination without cause should trigger acceleration of all unvested rollover equity and any unpaid earnout, and can also release the non-compete. Equally important, “for cause” triggers, which allow the buyer to terminate without those protections, should be narrowly defined so the buyer cannot easily manufacture a cause-based exit that strips protections and locks the seller into the covenant.
- Earnout protections. Pro-rata provisions can allow a near-miss on an EBITDA target to still pay most of the earnout. EBITDA means earnings before interest, taxes, depreciation, and amortization, and it is a common measure of practice profitability. A later earnout start date can also account for integration disruption in the first months after closing.
- Clinical autonomy. The agreement should specify which clinical decisions remain with the selling doctor and which transfer to the buyer’s management structure. Clear language can reduce friction around treatment planning and case acceptance.
- Tail malpractice insurance. Buyer-paid tail malpractice insurance can be a negotiable term in DSO and private equity deals. Seller-paid tail can materially reduce net proceeds, so many sellers attempt to shift this cost back to the buyer during LOI negotiations.
Many sellers prefer to have all LOI terms, including the full employment structure, negotiated before exclusivity begins and leverage declines.
Comparing Sell and Stay vs. Full Exit
A full exit, where the owner sells outright and walks away, can be the simplest structure but not always the strongest financial outcome. The better path can depend on practice size, the owner’s retirement horizon, and how much of the practice’s value is tied to the doctor’s personal patient relationships.
| Factor | Sell and Stay (Private Buyer) | Sell and Stay (DSO) |
|---|---|---|
| Post-close timeline | 30–90 days, flexible | 3–5 years, structured |
| Compensation mix | Flat fee or daily rate during work-back | Cash at close + 25–35% collections + equity rollover up to ~40% |
Control dynamics differ significantly between these paths. In a private-buyer sale, the seller usually retains clinical autonomy during the brief work-back but has no ownership or operational control, and the buyer directs the practice from day one. In a DSO affiliation, clinical autonomy is often preserved through the employment period, while administrative and operational control typically shifts to the DSO’s management structure.
Post-close obligations also diverge. Private-buyer deals usually require patient introductions and referral handoffs during the work-back, followed by a clean exit. DSO deals often tie the seller to production targets, earnout milestones, and equity vesting schedules that can extend several years.
The four-part journey of Understand Your Options → Create Competition → Find The Right Fit → Maximize Your Outcome can apply to both paths. A roughly even mix of private-buyer and DSO transactions can support a genuine side-by-side valuation rather than a recommendation shaped by a single preferred path.
Tax Considerations in Sell and Stay Structures
Tax treatment can be one of the most consequential and most frequently misunderstood parts of a sell-and-stay structure. Owners generally benefit from consulting a qualified CPA or tax advisor for guidance specific to their situation. The points below provide educational context rather than tax advice.
In a typical asset sale, proceeds received at close for goodwill and certain other intangible assets may qualify for long-term capital gains treatment. Capital gains are usually taxed at a lower federal rate than ordinary income, which can matter when a DSO deal generates a large lump-sum payment at closing.
Post-sale employment compensation, such as the 25–35% of collections earned during the work-back period, is usually taxed as ordinary income at the seller’s marginal rate. Equity rollover components in DSO deals, where up to roughly 40% of deal value may be paid in DSO equity rather than cash, can carry their own tax timing considerations. Gains on that equity are typically not realized until a future recapitalization or platform sale.
Multi-year, multi-structure financial forecasting that models after-tax proceeds across deal structures and time horizons, such as 3, 5, 7, and 10 years, can help owners compare options on an apples-to-apples basis rather than reacting only to a headline number.
Core Terms in DSO Sell and Stay Agreements
DSO affiliation agreements tend to be more standardized than private-buyer contracts, yet standardized terms can still be negotiable. A clear picture of the typical structure often becomes the starting point for improving terms.
The multi-year employment agreement discussed earlier usually covers compensation rate, non-compete geography and duration, restrictive covenants, termination provisions, and clinical autonomy. Key components often include the following elements.
- Compensation. The seller’s compensation typically shifts to 25–35% of collections during the employment period. Specialty work such as implants, oral surgery, or orthodontics can sometimes command a higher percentage.
- Equity rollover. DSO sell-and-stay transactions frequently include an equity rollover component, sometimes called the “second bite of the apple,” which allows the seller to participate in a future platform recapitalization or sale. This equity can be held at the joint-venture level, which may provide distributions and a higher floor but lower ceiling, or at the holding-company level, which often has no distributions but a higher potential upside.
- Earnouts. Earnouts are contingent payments typically spanning 1–3 years post-close, tied to post-acquisition financial targets. Pro-rata provisions and later start dates can make earnouts feel less punitive if early integration affects performance.
- Non-compete. Non-competes in DSO transactions are routinely overreaching in geographic scope and duration compared with the typical 2–5 year, 5–10 mile scope discussed earlier. Sellers often use leverage during LOI negotiations to secure the least restrictive limitations that still satisfy the buyer.
Some advisory teams evaluate DSO buyers in a manner similar to investments, looking at profitability, growth trajectory, management quality, and financial backing. Buyers with a history of poor post-close environments can be screened out so owners focus on well-backed partners with stronger reputations.
Schedule a free, confidential discovery call with McLerran & Associates to see how a structured, auction-like bid process, often generating around 10 offers, can create competitive tension that supports stronger DSO terms.
Frequently Asked Questions
How does McLerran & Associates determine which transition path is right for my practice?
Each engagement typically starts with the owner’s “why,” including goals, timing, and key concerns, before any path is suggested. From there, the team builds a comprehensive, CPA-led EBITDA analysis and delivers a side-by-side valuation that shows the practice’s worth in both the private-buyer and DSO markets. Practices generating roughly $1–1.5 million in annual revenue often fit a doctor-to-doctor sale, while larger practices at $1.5 million and above can frequently access the DSO market. Owners in the middle range can benefit from seeing both numbers before deciding, and recommendations are framed around the owner’s likely outcome rather than a single preferred structure.
What happens to my staff and patients during a sell-and-stay transition?
Protecting staff and patients can be just as important as maximizing price. A strong process aims to secure a solid financial result while also finding a buyer whose strategy, structure, and support model align with the owner’s vision for the practice after the transition. In practice, an advisor often serves as a buffer between seller and buyer throughout the process to protect goodwill and momentum.
Sellers are usually coached on early staff communication, retention incentives, and a structured patient introduction plan. That plan can include a personalized letter endorsing the buyer by name, in-person introductions during the final weeks, and seller availability for patient questions during the early post-close period. These steps can help keep patient attrition well below 10% in many cases.
How is McLerran & Associates different from a local dental broker or a generalist M&A firm?
A local broker who knows only a few buyers may provide limited market exposure, lighter valuation work, and less aggressive bidding, because buyers understand that those brokers transact infrequently and may price offers accordingly. A multi-vertical advisor can bring deal experience but may lack the dental-only depth to read specialty-by-specialty dynamics, regional buyer appetite, or the nuances of DSO equity structures.
McLerran focuses solely on dental practices, has evaluated more than 10,000 practices, and runs a structured, auction-like process that typically generates around 10 offers per listing. Reported transaction rates of roughly 85–90% compare with an industry norm closer to 35–40%. The CPA-led EBITDA analysis is designed to be diligence-grade work completed before the deal goes to market so valuations are more likely to hold under buyer scrutiny.
Can I negotiate a shorter work-back period in a DSO deal?
A shorter post-close commitment can be possible in certain situations, such as when the selling doctor has already reduced clinical days, when the practice has multiple associate dentists who provide continuity, or when the buyer’s integration model relies less on the seller’s ongoing production. Even so, a multi-year commitment remains standard in many DSO transactions.
A meaningful portion of total proceeds, through earnouts and equity vesting, is often tied to the seller’s continued engagement. For that reason, many sellers work with advisors to negotiate the full employment structure, including term length, schedule, and protections that apply if the arrangement ends early.
Is now a good time to sell a premier dental practice?
Demand for premier, high-producing practices remains strong in many markets, and valuations for Class A assets can be near historic highs. Timing, however, tends to be practice-specific. The right moment often depends on the owner’s financial readiness, the practice’s current trajectory, and market conditions in the relevant region and specialty.
Advisors can provide a candid assessment of how a specific practice is positioned today. If the owner is not ready, some firms will update the valuation later at no charge rather than encourage a deal that may not serve the client’s long-term interests.
Next Steps for Evaluating a Sell and Stay Transition
A sell-and-stay transition can be one of the most significant financial decisions in a dentist’s career, and the right path usually depends on practice size, personal goals, and the fit with a specific buyer. McLerran & Associates guides owners through each step of the four-part journey: Understand Your Options → Create Competition → Find The Right Fit → Maximize Your Outcome.
With roughly 2,000 successful practice sales, approximately $2 billion in closed transaction volume, and a transaction rate of roughly 85–90%, McLerran offers depth, a broad buyer pool, and focused sell-side advocacy for premier practice owners. The firm’s role extends beyond listing practices to actively managing the process through closing.
Schedule a free, confidential discovery call with McLerran & Associates to discuss your practice, your goals, and your options. Call (512) 900-7989, email info@dentaltransitions.com, or visit dentaltransitions.com/contact-us.
